論文

査読有り 国際誌
2017年3月23日

Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients.

Scientific reports
  • Takashi Nomizo
  • Hiroaki Ozasa
  • Takahiro Tsuji
  • Tomoko Funazo
  • Yuto Yasuda
  • Hironori Yoshida
  • Yoshitaka Yagi
  • Yuichi Sakamori
  • Hiroki Nagai
  • Toyohiro Hirai
  • Young Hak Kim
  • 全て表示

7
開始ページ
45124
終了ページ
45124
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1038/srep45124

This study was intended to determine the efficacy of nivolumab, we evaluated treatment response with respect to PD-1/PD-L1 SNPs among patients with NSCLC. A total of 50 patients with NSCLC were treated with nivolumab and were also evaluated for PD-1/PD-L1 single nucleotide polymorphisms (SNPs) from plasma DNA. We investigated the association among PD-1/PD-L1 SNPs, objective response rate (ORR) and progression-free survival (PFS). Two of seven SNPs studied showed association with ORR and PFS, with maximum evidence at the marker rs2282055. The ORR was 25%, 15%, and 0% for the G/G, G/T and T/T genotypes of PD-L1 rs2282055, respectively. The G allele of PD-L1 rs2282055 was significantly associated with better clinical response compared with the T allele (P = 0.0339 [Cochran-Armitage trend test]). The median PFS time was 2.6 months (95% confidence interval [CI], 1.8 months to 4.3 months) for the G/G and G/T genotypes and 1.8 months (95% confidence interval [CI], 0.4 months to 2.2 months) for the T/T genotype (P = 0.0163). Moreover, the C/C and C/G genotypes of PD-L1 rs4143815 were significantly associated with better ORR and PFS in NSCLC patients treated with nivolumab. These results suggest that rs2282055 and rs4143815 may be a biomarker for the efficacy of nivolumab.

リンク情報
DOI
https://doi.org/10.1038/srep45124
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/28332580
PubMed Central
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5362817
ID情報
  • DOI : 10.1038/srep45124
  • PubMed ID : 28332580
  • PubMed Central 記事ID : PMC5362817

エクスポート
BibTeX RIS